SCHEMBL13428984

SCHEMBL13428984

Cn1cc(CN(Cc2ccn(C)n2)c2cccc(Oc3cc(=O)[nH]c4ccccc34)c2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
KDM4E B2RXH2 5/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
KDM4C Q9H3R0 1/20 0.33
GRM5 P41594 1/20 0.32
CYP11B1 P15538 1/20 0.32
KCNH2 Q12809 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 5/20 0.31
HPGD P15428 3/20 0.31
MAPT P10636 2/20 0.31
USP2 O75604 2/20 0.31
ALOX15 P16050 2/20 0.31
HSD17B10 Q99714 1/20 0.31
PARG Q86W56 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13428985 0.75 MEN1 (0.41) KDM4EGRM5KMT2AMEN1GAA
SCHEMBL13429163 0.74 AXL (0.41) GRM5HPGDMAPTBRD4
SCHEMBL3216704 0.70 KDM4C (0.53) FNTAFNTBKDM4EKDM4CHSD17B10
SCHEMBL13429155 0.70 CCNC (0.47) CYP11B1HPGDMAPTBRD4
SCHEMBL13429036 0.67 HPGD (0.46) KDM4EGRM5ALDH1A1HPGDHSD17B10
SCHEMBL3227446 0.66 AXL (0.49) BRD4
SCHEMBL13429174 0.65 AXL (0.50) BRD4
SCHEMBL13429074 0.64 ABCG2 (0.51) KDM4EKMT2AMEN1ALDH1A1HPGD
SCHEMBL13429069 0.64 CYP1A2 (0.53) KDM4EGRM5KMT2AMEN1ALDH1A1
SCHEMBL3225576 0.64 KIF11 (0.47) KDM4EKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA FNTA 2462/4885FNTB 3130/4885KDM4E 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.